Viral Efficacy Models

IBT’s established viral efficacy models can help you assess the effectiveness of your antiviral drugs, vaccines, or other interventions in inhibiting or eliminating viral infections.

If you are working on anti-viral drug discovery, vaccine development, or studying viral infections, viral efficacy models can provide valuable insights into the effectiveness of your interventions in a controlled laboratory environment. IBT has several viral efficacy models which can be complemented with downstream assays to thorough evaluate efficacy and protection from disease.

Evaluating the effectiveness of therapeutics is crucial in preclinical research helps to understand how well a given treatment can inhibit viral replication, reduce viral load, and mitigate the impact of the infection.

Key Aspects & Benefits of evaluating therapeutics efficacy

Mechanism of Action

Understanding how a therapeutic candidate works at the molecular or cellular level is fundamental. Efficacy studies help validate the proposed mechanism of action and ensure that the therapeutic is affecting the target as intended.

Dose-Response

Efficacy studies help establish the relationship between the dose of the therapeutic and its biological effect. This information is critical for determining the optimal dosage for effective treatment while minimizing potential side effects.

Lead Identification

Screening of lead candidates in an efficacy study is crucial to the decision-making process helping one identify and advance a therapeutic candidate to the next stages of product development. Positive efficacy results increase confidence in the potential success of the therapeutic.

Treatment Regimen

Efficacy studies help researchers optimize treatment regimens, including dosing schedules and durations. This optimization ensures the most effective and efficient use of the therapeutic

A comprehensive and well-designed evaluation strategy enhances the quality of evidence, informs clinical decision-making, and contributes to advancing preclinical therapeutics. It is essential to consider two evaluation formats to achieve a robust assessment:

Animal models are essential for investigating viral infections, evaluating antiviral treatments, understanding immune responses, and assessing the safety and effectiveness of preclinical vaccines. They provide a detailed understanding of how viruses spread, interact with hosts, and how interventions impact biological systems. Additionally, these models create a controlled environment for evaluating potential antiviral candidates before progressing to more complex in vivo studies. Complementary downstream assays like serology, plaque assays, and neutralization assays further enhance our understanding by offering insights into immune responses, viral infectivity, and treatment effectiveness alongside in vivo investigations.

Cell-based viral efficacy models involve the use of cell cultures or tissue-based systems to assess the activity of antiviral agents, evaluate viral replication, investigate viral-host interactions, and study the mechanisms of action of potential treatments. These models provide a controlled environment for testing and screening potential antiviral candidates before proceeding to more complex in vivo studies.

IBT’s Established Animal Viral Efficacy Models

Influenza Virus Flaviviruses: Dengue and Zika Virus Alphaviruses: Chikungunya and Venezuelan Equine Encephalitis Virus Respiratory Syncytial Virus DNA Viruses: Herpes Simplex Virus, Cytomegalovirus, Vaccinia, and Adenovirus Filoviruses: Ebola and Marburg Viruses

Hemagglutination Inhibition Assay Microneutralization Assay Pseudovirus Neutralization Assay QPCR Resistance Assays Yield Reduction Plaque assays

IBT’s Established Animal Viral Efficacy Models

IBT’s Established Cell-Based Viral Assays

IBT offers experienced researchers in both realms to help investigators efficiently achieve comprehensive results.

IN-VITRO Services

ANIMAL SERVICES

By Diseases Target